7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prevalence of Severe Visual Disability Among Preterm Children With Retinopathy of Prematurity and Association With Adherence to Best Practice Guidelines

      research-article
      , MD, PhD 1 , 2 , 3 , , , MD, PhD 4 , , MD, PhD 1 , 2 , , MD 5 , , MD, PhD 6 , , MD, PhD 7 , , MD, PhD 3 , 8 , , MD, PhD 9
      JAMA Network Open
      American Medical Association

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What is the prevalence of visually disabling retinopathy of prematurity in Sweden and how is it associated with quality of care?

          Findings

          In this population-based cohort study of 1 310 227 infants born alive in Sweden in 2004 to 2015, 1 in 77 000 or 1 in 1000 very preterm infants (<32 weeks of gestational age) became severely visually disabled by retinopathy of prematurity. In 11 of 17 infants (65%), disability was considered avoidable because of nonadherence to best practice, as well as flaws in structural capacity.

          Meaning

          Severe visual impairment associated with retinopathy of prematurity is preventable in most cases.

          Abstract

          This cohort study investigates the prevalence of severe visual disability due to retinopathy of prematurity (ROP) among children in Sweden and examines the association between prevalence of disability and adherence to best practice guidelines for treatment of ROP.

          Abstract

          Importance

          Retinopathy of prematurity (ROP) can cause severe visual disability even in high-resource settings. A better understanding of the prevalence and processes leading to ROP-induced severe visual impairment may help health care professionals design preventive measures.

          Objectives

          To determine the prevalence of severe visual disability among children born preterm in Sweden, evaluate adherence to best practice, and determine the health system’s structural capacity.

          Design, Setting, and Participants

          Population-based, nationwide cohort study of 1 310 227 children born between January 1, 2004, and December 31, 2015, in Sweden, of whom 17 588 (1.3%) were born very preterm (<32 weeks of gestation). Children born preterm with a verified diagnosis of severe visual disability had their medical records reviewed for evaluation of ROP screening, diagnosis, and treatment. In addition, a questionnaire on structural capacity was sent to all ophthalmology departments.

          Exposures

          Stages 4 and 5 ROP.

          Main Outcomes and Measures

          The primary outcome was prevalence of severe visual disability (visual acuity ≤20/200 for both eyes) associated with ROP stages 4 and 5. Secondary outcomes included adherence to national ROP guidelines using a predefined protocol with 15 key performance indicators for screening, diagnosis, and treatment; assessment of whether visual disability was deemed avoidable; and examination of structural capacity, including information on equipment and facilities, staffing, and patients.

          Results

          Seventeen children (10 boys; mean [range] birth weight, 756 [454-1900] g; mean [range] gestational age, 25 [22-33] weeks) became severely visually disabled because of ROP, corresponding to a prevalence of 1 in 1000 very preterm infants (<32 weeks of gestational age) and 1 in 77 000 for all live births. Severe visual impairment was considered potentially avoidable in 11 of 17 affected children (65%) owing to untimely or no screening, missed diagnosis, or untimely and suboptimal treatment. Large variations in infrastructure (facilities, guidelines, staffing, and annual patient numbers) were also identified as potential contributors to these findings.

          Conclusions and Relevance

          Retinopathy of prematurity still causes severe visual disability in Sweden, resulting in 1 affected infant per 1000 very preterm births. In most of these infants, noncompliance with best practice was identified, indicating that a significant proportion could have been avoided.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

          To determine whether earlier treatment using ablation of the avascular retina in high-risk prethreshold retinopathy of prematurity (ROP) results in improved grating visual acuity and retinal structural outcomes compared with conventional treatment. Infants with bilateral high-risk prethreshold ROP (n = 317) had one eye randomized to early treatment with the fellow eye managed conventionally (control eye). In asymmetric cases (n = 84), the eye with high-risk prethreshold ROP was randomized to early treatment or conventional management. High risk was determined using a model based on the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity natural history cohort. At a corrected age of 9 months, visual acuity was assessed by masked testers using the Teller acuity card procedure. At corrected ages of 6 and 9 months, eyes were examined for structural outcome. Outcomes for the 2 treatment groups of eyes were compared using chi2 analysis, combining data for bilateral and asymmetric cases. Grating acuity results showed a reduction in unfavorable visual acuity outcomes with earlier treatment, from 19.5% to 14.5% (P =.01). Unfavorable structural outcomes were reduced from 15.6% to 9.1% (P<.001) at 9 months. Further analysis supported retinal ablative therapy for eyes with type 1 ROP, defined as zone I, any stage ROP with plus disease (a degree of dilation and tortuosity of the posterior retinal blood vessels meeting or exceeding that of a standard photograph); zone I, stage 3 ROP without plus disease; or zone II, stage 2 or 3 ROP with plus disease. The analysis supported a wait-and-watch approach to type 2 ROP, defined as zone I, stage 1 or 2 ROP without plus disease or zone II, stage 3 ROP without plus disease. These eyes should be considered for treatment only if they progress to type 1 or threshold ROP. Early treatment of high-risk prethreshold ROP significantly reduced unfavorable outcomes to a clinically important degree. Additional analyses led to modified recommendations for the use of peripheral retinal ablation in eyes with ROP. Long-term follow-up is being conducted to learn whether the benefits noted in the first year after birth will persist into childhood.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Retinopathy of prematurity.

            The immature retinas of preterm neonates are susceptible to insults that disrupt neurovascular growth, leading to retinopathy of prematurity. Suppression of growth factors due to hyperoxia and loss of the maternal-fetal interaction result in an arrest of retinal vascularisation (phase 1). Subsequently, the increasingly metabolically active, yet poorly vascularised, retina becomes hypoxic, stimulating growth factor-induced vasoproliferation (phase 2), which can cause retinal detachment. In very premature infants, controlled oxygen administration reduces but does not eliminate retinopathy of prematurity. Identification and control of factors that contribute to development of retinopathy of prematurity is essential to prevent progression to severe sight-threatening disease and to limit comorbidities with which the disease shares modifiable risk factors. Strategies to prevent retinopathy of prematurity will depend on optimisation of oxygen saturation, nutrition, and normalisation of concentrations of essential factors such as insulin-like growth factor 1 and ω-3 polyunsaturated fatty acids, as well as curbing of the effects of infection and inflammation to promote normal growth and limit suppression of neurovascular development. Copyright © 2013 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Neurodevelopmental Outcomes Among Extremely Preterm Infants 6.5 Years After Active Perinatal Care in Sweden

              Active perinatal care increases the rate of survival of extremely preterm infants, but there are concerns that improved survival might increase the rate of disabled survivors.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                4 January 2019
                January 2019
                4 January 2019
                : 2
                : 1
                : e186801
                Affiliations
                [1 ]Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
                [2 ]Department of Neonatal Medicine, Karolinska University Hospital, Stockholm, Sweden
                [3 ]Swedish Neonatal Quality Registry, Umeå, Sweden
                [4 ]Department of Ophthalmology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
                [5 ]Department of Pediatric Ophthalmology and Strabismus, St Erik Eye Hospital, Stockholm, Sweden
                [6 ]The Swedish National Patient Insurance, Stockholm, Sweden
                [7 ]Department of Clinical Sciences, Ophthalmology, Lund University, Lund, Sweden
                [8 ]Department of Clinical Science/Pediatrics, Umeå University, Umeå, Sweden
                [9 ]Department of Neuroscience/Ophthalmology, Uppsala University, Uppsala, Sweden
                Author notes
                Article Information
                Accepted for Publication: November 9, 2018.
                Published: January 4, 2019. doi:10.1001/jamanetworkopen.2018.6801
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Norman M et al. JAMA Network Open.
                Corresponding Author: Mikael Norman, MD, PhD, Division of Pediatrics, CLINTEC, Novum, Blickagången 6A, Karolinska Institutet, SE 141 57 Stockholm, Sweden ( mikael.norman@ 123456ki.se ).
                Author Contributions: Dr Norman had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Norman, Hellström, Håkansson, Holmström.
                Acquisition, analysis, or interpretation of data: All authors.
                Drafting of the manuscript: Norman, Hellström, Holmström.
                Critical revision of the manuscript for important intellectual content: Hellström, Hallberg, Wallin, Gustafson, Tornqvist, Håkansson.
                Statistical analysis: Norman.
                Obtained funding: Norman.
                Administrative, technical, or material support: Hellström, Hallberg, Gustafson, Håkansson, Holmström.
                Supervision: Norman.
                Conflict of Interest Disclosures:  Dr Norman reported grants from the Swedish Order of Freemasons’ Foundation for Children’s Welfare during the conduct of the study as well as grants from the Swedish Heart-Lung Foundation and personal fees from the Swedish Medical Journal, the Swedish National Patient Insurance, Studentlitteratur AB, and Liber AB outside the submitted work. Dr Tornqvist reported grants from the Foundation for the Visually Impaired in Southern Sweden during the conduct of the study. No other disclosures were reported.
                Funding/Support: Funding for this study was provided by Swedish Order of Freemasons’ Foundation for Children’s Welfare. The Swedish Neonatal Quality Register is funded by the Swedish Government (Ministry of Health and Social Affairs) and the County Councils.
                Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Additional Contributions: We acknowledge all Swedish colleagues entering data in the Swedish National Register for Retinopathy of Prematurity. We thank all pediatric and ophthalmology departments in Sweden for administrative support and for making medical records available for us to scrutinize.
                Article
                zoi180279
                10.1001/jamanetworkopen.2018.6801
                6324320
                30646195
                9f2a0145-1a5f-47e9-a3b9-e670710b9c00
                Copyright 2019 Norman M et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 22 October 2018
                : 9 November 2018
                : 9 November 2018
                Categories
                Research
                Original Investigation
                Online Only
                Pediatrics

                Comments

                Comment on this article